Sara Buhrlage is heading a cancer chemical biology lab at the DFCI. Her lab has established an integrated DUB-focused platform comprised of DUB-targeted libraries with novel scaffolds and chemotypes and a suite of established and novel biochemical and chemoproteomic assays that has accelerated development of selective probes and annotation of function and translational potential for multiple DUBs. The group is now building on these successes to generate a deep bench of inhibitor focused projects as well as expanding the platform through innovation in DUB ligand mechanisms of action and DUB-focused technologies.